Medicare Appeal Packet for Integra® Wound Matrix (Thin)

Total Page:16

File Type:pdf, Size:1020Kb

Medicare Appeal Packet for Integra® Wound Matrix (Thin) Medicare Appeal Packet for Integra® Wound Matrix (Thin) As a service to our customers, Integra LifeSciences Corporation has assembled this packet of information to assist you with the Medicare appeal process. Included in this packet are as follows: Information on how to appeal a Medicare Claim Determination Sample Letter of Medical Necessity Sample Statement of Medical Necessity Package Insert FDA Clearance Letter Bibliography of clinical articles relative to the Integra® Matrix Family of Products Literature Request Form If you would like to obtain clinical articles to help support the appeal, please contact the reimbursement hotline at 1-877-444-1122, Option 3, option 1 or email the literature request form to [email protected]. Please have readily available, the specific Integra® product that is being appealed and the indication for which the product was used in order for us to provide you with relevant clinical literature. Thank you. Disclaimer: Integra has used reasonable efforts to provide accurate coding advice, but this advice should not be construed as providing clinical advice, dictating reimbursement policy or substituting for the judgment of a practitioner. Integra LifeSciences Corporation assumes no responsibilities or liabilities for the timeliness, accuracy and completeness of the information contained herein. Since reimbursement laws, regulations and payor policies change frequently, it is recommended that providers consult with their payors, coding specialists and/or legal counsel regarding coverage, coding and payment issues. Integra and the Integra logo are registered trademarks of Integra LifeSciences Corporation in the United States and/or other countries. ©2020 Integra LifeSciences Corporation. All rights reserved. T – 1561033 – 1 (2020-04) 1564512 – 1 (2020-04) General Information: Individuals enrolled in Medicare may file an appeal if they believe Medicare should have paid for, or did not pay enough for, an item or service that they received. An individual’s appeal rights are on the back of the Medicare Summary Notice (MSN) mailed to Medicare beneficiaries after they receive services. The MSN explains why a bill was not paid and how to file an appeal. The providers and suppliers of services that file claims on behalf of Medicare beneficiaries may also file appeals. The Medicare Part B Fee-for-Service Appeals Process: Https://www.cms.gov/Medicare/Appeals-and- Grievances/OrgMedFFSAppeals/RedeterminationbyaMedicareContractor Monetary Level of Appeal Type Time Limit for Filing Threshold Appeal Request to be Met First Level Redetermination by a Within 120 days of None Medicare Contractor receipt of the notice of initial determination Second Reconsideration by a Within 180 days from the None Level Qualified Independent date of receipt of the Contractor notice of the redetermination Third Decision by Office of Within 60 days of receipt Minimum of Level Medicare Hearings and of the reconsideration $170 Appeals (OMHA) decision Fourth Review by the Medicare Within 60 days from the None Level Appeals Council date of receipt of the notice of OMHA’s decision or dismissal Fifth Judicial Review in Federal Within 60 calendar days Minimum of Level District Court from the date it receives $1670 notice of the Council’s decision Documentation to include with your Appeal request In an effort to present a solid case to Medicare or any other insurance carrier that the use of Integra® Wound Matrix (Thin) was/is in the best interest of the patient, it is important to submit with the appeal, pertinent health information pertaining to the treatment of the wound. Examples of relevant information to include would be: History and Physical documentation Progress/Office notes specific to the treatment of the wound Operative Reports specific to the treatment of the wound Pictures of the wound Documentation that may illustrate previous wound treatments Letter of Medical Necessity: If a procedure was deemed by the insurer as “not medically necessary,” it may be required that you prove medical necessity as part of your appeal. In addition to providing relevant health information specific to the treatment of the patient’s wound, a Letter of Medical Necessity should accompany the appeal to help further justify the use of Integra® Wound Matrix (Thin). If a Letter of Medical Necessity has been requested, we have available a sample letter, as well as a sample template (on the following two pages) to assist you in the process. Also available, upon request, Integra LifeSciences Corporation can provide you with clinical articles to help support your claim. Please feel free to contact our Reimbursement department at 1-877-444-1122 option 3, option 1 or email the literature request form to [email protected]. For more information regarding Medicare, please go to http://www.cms.hhs.gov/ Disclaimer: Integra has used reasonable efforts to provide accurate coding advice, but this advice should not be construed as providing clinical advice, dictating reimbursement policy or substituting for the judgment of a practitioner. Integra LifeSciences Corporation assumes no responsibilities or liabilities for the timeliness, accuracy and completeness of the information contained herein. Since reimbursement laws, regulations and payor policies change frequently, it is recommended that providers consult with their payors, coding specialists and/or legal counsel regarding coverage, coding and payment issues. Integra and the Integra logo are registered trademarks of Integra LifeSciences Corporation in the United States and/or other countries. ©2020 Integra LifeSciences Corporation. All rights reserved Sample Letter of Medical Necessity: (Please type on physician’s letterhead) Date: << Insurance Company>> <<Address>> <<City, State, Zip Code>> Re: <<Patient’s Name>> Policy Number: << xxxxxx>> Group Number <<xxxxxx>> To Whom It May Concern: Enclosed for your review, are clinical articles documenting the effective use of Integra® Wound Matrix (Thin). The attached Statement of Medical Necessity and information pertaining to <<Patient’s Name>> clinical history and diagnosis clearly demonstrate that Integra® Wound Matrix (Thin) is the treatment of choice. Please send me written verification of coverage and payment for the procedure noted for <<Patient’s Name>> as soon as possible. If you have any questions pertaining to the clinical history or my treatment plan, please call me directly at: <<Office Phone Number>> Thank you for your immediate attention to this matter. Sincerely, <<MD’s Name>> Enclosure: Statement of Medical Necessity Estimate of Professional and Facility Charges Patient Records CC: <<Patient Name>> Medical Record File <<Facility billing contract>> Sample Statement of Medical Necessity for Proposed Procedure Utilizing Integra® Wound Matrix (Thin) PATIENT NAME: _____________________ GENDER: M or F ADDRESS: _________________________ DATE OF BIRTH: _______ _________________________ FACILITY NAME: ______________ PHONE: _________________________ INSURANCE CO: _________________ SUBSCRIBER: ________________ GROUP NAME: ___________________ DATE OF DIAGNOSIS: _________ DIAGNOSIS: ___________________________________________________________ ICD-10 DIAGNOSIS CODE(S): _________________ SIZE OF WOUND: _________ ETIOLOGY OF WOUND: ___________________ DATE OF DIAGNOSIS: ________ DETAILED DESCRIPTION OF WOUND: ____________________________________ ______________________________________________________________________ ______________________________________________________________________ OTHER MEDICAL CONDITIONS: __________________________________________ ______________________________________________________________________ TREATMENT PLAN: ____________________________________________________ ______________________________________________________________________ _____________________________________________________________________ MEDICAL NECESSITY OF USING INTEGRA® WOUND MATRIX (THIN) FOR THIS WOUND: ______________________________________________________________________ ______________________________________________________________________ ______________________________________________________________________ ______________________________________________________________________ PHYSICIAN NAME: (please print) _________________________________________ ADDRESS: ___________________________________________________________ PHYSICIAN SIGNATURE: ___________________________ DATE: _____________ _ Post-Application Integra® Wound Matrix 1. Change the secondary dressing as needed. Frequency of secondary dressing change will Integra® Wound Matrix (Thin) ® be dependent upon volume of exudate produced, type of dressing used and the clinician’s need to inspect the wound bed for signs of infection or healing. DESCRIPTION Note: If hematoma or excess exudate collect under the sheet, Integra® Wound Matrix and Integra® Wound Matrix (Thin) are collagen- small openings can be cut in the sheet to allow fluid to drain. glycosaminoglycan wound dressings that maintain and support a healing 2. As healing occurs, sections of Integra Wound Matrix and Integra Wound Matrix (Thin) environment for wound management. Integra Wound Matrix (Thin) has may gradually peel and may be removed during dressing changes. Do not forcibly remove 50% less collagen compared to each of the corresponding sq cm sizes sections of Integra Wound Matrix or Integra Wound Matrix (Thin) that may adhere to of Integra Wound Matrix. the wound. On inspection, if Integra Wound Matrix or Integra Wound
Recommended publications
  • Ultra Pure Collagen Regenerative Medicine
    ENG Ultra pure collagen Regenerative medicine Because we are committed to limiting uncertainty, Specifications Integra continues to develop new products in regenerative technology. • An established product line with proven results. • Outstanding safety profile. • Integra LifeSciences has leveraged over 30 years of science and innovation in the development of • Implanted in over 900 000 patients. collagen technology. • Integra LifeSciences’ extensive collagen purification process, advanced bio-engineering proficiency, and manufacturing experience add value to our products designed for protection, regeneration and repair of human tissue in various clinical applications. • Ultra Pure Collagen™ is the base material of implants used successfully in over 10 million procedures worldwide. • Ultra Pure Collagen™ has been used in general surgery, burn surgery, neurosurgery, plastic and reconstructive surgery, peripheral nerve/tendon surgery & orthopedic surgery. Products for sale in Europe, Middle-East and Africa only Ultra pure collagen Regenerative medicine How was Integra LifeSciences’ Collagen Matrix Created? For over thirty years, Integra LifeSciences has been a leader in developing and manufacturing high quality collagen implants. In the early 1970’s, John F. Burke, MD, chief of Trauma Services at Massachusetts General Hospital and Shriners Burns Institute, identified the need to improve skin restoration of severely burned patients. While patient related donor skin was an option, immunorejection was a critical issue. Dr. Burke theorized that an artificial means to cover the skin might offer positive results without the potential for donor skin rejection. Dr. Burke collaborated with Dr. Ioannas Yannas, a professor What Makes Integra LifeSciences’ Collagen at MIT with a specialization in material sciences and Unique? physical chemistry, to develop a biocompatible product to improve wound healing.
    [Show full text]
  • Hesitant Steps from the Artificial Skin to Organ Regeneration
    Hesitant steps from the artificial skin to organ regeneration The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Yannas, Ioannis V. “Hesitant Steps from the Artificial Skin to Organ Regeneration.” Regenerative Biomaterials (June 26, 2018). As Published http://dx.doi.org/10.1093/RB/RBY012 Publisher Oxford University Press (OUP) Version Final published version Citable link http://hdl.handle.net/1721.1/120040 Terms of Use Creative Commons Attribution 4.0 International license Detailed Terms https://creativecommons.org/licenses/by/4.0/ Regenerative Biomaterials, 2018, 189–195 doi: 10.1093/rb/rby012 Advance Access Publication Date: 26 June 2018 Review Hesitant steps from the artificial skin to organ regeneration Ioannis V. Yannas* Downloaded from https://academic.oup.com/rb/article-abstract/5/4/189/5045640 by MIT Libraries user on 14 January 2019 Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA *Correspondence address. Department of Mechanical Engineering, Massachusetts Institute of Technology, Room 3-332, 77 Mass. Ave., Cambridge, MA 02139-4307, USA. E-mail: [email protected] Received 7 May 2018; accepted on 10 May 2018 Abstract This is a historical account of the steps, both serendipitous and rational, that led my group of stu- dents and colleagues at MIT and Harvard Medical School to discover induced organ regeneration. Our research led to methods for growing back in adult mammals three heavily injured organs, skin, peripheral nerves and the conjunctiva. We conclude that regeneration in adults is induced by a modification of normal wound healing.
    [Show full text]
  • Skin Resurfacing for the Burned Patient
    00. ם NEW DIRECTIONS IN PLASTIC SURGERY, PART II 0094–1298/02 $15.00 SKIN RESURFACING FOR THE BURNED PATIENT Ryan A. Stanton, MD, and David A. Billmire, MD The ultimate goal and eventual reward in factory quality of life and adapt a functional treating severely burned patients is the estab- postburn lifestyle. A rough indicator of indi- lishment of a protective barrier from the out- vidual psychologic rehabilitation is reflected side world. Skin resurfacing for the burned by employment status. Patients who return to patient has made large strides since the mid- work after burn injury have less behavioral twentieth century. Improvements in resuscita- avoidance, higher self esteem, and greater at- tion, management of inhalation injuries, and tention to goals. It has been shown that the other advances in critical care are responsible most significant predictors of return to work for survival rates in burned patients nearly are involvement of the hand, grafting, size of doubling since the 1950s, increasing by al- burn, and age. Patients younger than 45 have most 1% each year.49, 57 Several factors have a higher return to work rate.74 The care of a contributed extensively to the evolution of severely burned patient requires the infra- clinical burn care, including a better under- structure of a dedicated burn center with in- standing of the critical need for adequate terdisciplinary involvement of nursing, coun- fluid resuscitation immediately postburn, seling, group therapy, and occupational and prophylaxis against wound sepsis and its physical therapy. Interventions designed to complications, the importance of adequate aid adjustment, work hardening, and other nutritional support, burn pathophysiology rehabilitative services and marital and family and its inflammatory mediators, management therapy are also important.
    [Show full text]
  • Burke John Francis (“Jack”) Burke Was Born on July 22, 1922 in Chicago, the First of Three Children Born to Francis A
    John Francis Burke John Francis (“Jack”) Burke was born on July 22, 1922 in Chicago, the first of three children born to Francis A. Burke, a railroad man, and Mary Biaggi. He died November 2, 2011 of pancreatic cancer. He filled those 89 years with grace and wry humor through many phases, including chemical engineer, Army Air Corps pilot (he enlisted the day after Pearl Harbor), surgeon, educator, homespun philosopher, administrator, and one of the most remarkably innovative surgeon-scientists of the post-War era. By the rigorous standard proposed to the University by President Faust, paraphrased as “to perpetuate knowledge to posterity”, he stands tall. Consider but three of many examples of his life’s work. As long as Western Civilization survives, surgeons the world over will be guided by his sentinel work on the enlightened use of antibiotics in the perioperative period to reduce the risk of bacterial infection. Prior to his systematic investigations of the prophylactic use of antibiotics to reduce surgical infection, the concept of prophylactic antibiotics was characterized by doubt, conflicting opinions, and a paucity of data. Secondly, while others have and will inevitably use further developments in science to enhance Jack Burke’s unique contributions to tissue engineering in the form of the creation of artificial skin, his concepts of this singular advance in tissue engineering long before the phrase “tissue engineering” even existed, will drive those efforts throughout posterity. The insightful recognition of the essential concepts required for artificially replacing human skin, coupled with the integration of the expertise of Ioannis V. Yannas, Professor of fibers and polymers at MIT, brought forth the amalgam of a silicon outer sheet over a scaffolding of molecular material drawn from cow tendon and shark’s cartilage.
    [Show full text]
  • Skin Substitutes for Treating Chronic Wounds: Technical Brief
    Technology Assessment Program Skin Substitutes for Treating Chronic Wounds Technical Brief Project ID: WNDT0818 February 2, 2020 Technology Assessment Program - Technical Brief Project ID: WNDT0818 Skin Substitutes for Treating Chronic Wounds Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. HHSA 290-2015-00005-I Prepared by: ECRI Institute - Penn Medicine Evidence-Based Practice Center Plymouth Meeting / Philadelphia, PA Investigators: D. Snyder, Ph.D. N. Sullivan, B.A. D. Margolis, M.D., Ph.D. K. Schoelles, M.D., S.M. ii Key Messages Purpose of Review To describe skin substitute products commercially available in the United States used to treat chronic wounds, examine systems used to classify skin substitutes, identify and assess randomized controlled trials (RCTs), and suggest best practices for future studies. Key Messages • We identified 76 commercially available skin substitutes to treat chronic wounds. The majority of these do not contain cells and are derived from human placental membrane (the placenta’s inner layer), animal tissue, or donated human dermis. • Included studies (22 RCTs and 3 systematic reviews) and ongoing clinical trials found during our search examine approximately 25 (33%) of these skin substitutes. • Available published studies rarely reported whether wounds recurred after initial healing. Studies rarely reported outcomes important to patients, such as return of function and pain relief. • Future studies may be improved by using a 4-week run-in period before study enrollment and at least a 12-week study period. They should also report whether wounds recur during 6-month followup.
    [Show full text]
  • A Concise Review on Tissue Engineered Artificial Skin
    cells Review A Concise Review on Tissue Engineered Artificial Skin Grafts for Chronic Wound Treatment: Can We Reconstruct Functional Skin Tissue In Vitro? Agata Przekora Department of Biochemistry and Biotechnology, Medical University of Lublin, Chodzki 1 Street, 20-093 Lublin, Poland; [email protected]; Tel.: +48-81-448-7026 Received: 26 May 2020; Accepted: 21 June 2020; Published: 6 July 2020 Abstract: Chronic wounds occur as a consequence of a prolonged inflammatory phase during the healing process, which precludes skin regeneration. Typical treatment for chronic wounds includes application of autografts, allografts collected from cadaver, and topical delivery of antioxidant, anti-inflammatory, and antibacterial agents. Nevertheless, the mentioned therapies are not sufficient for extensive or deep wounds. Moreover, application of allogeneic skin grafts carries high risk of rejection and treatment failure. Advanced therapies for chronic wounds involve application of bioengineered artificial skin substitutes to overcome graft rejection as well as topical delivery of mesenchymal stem cells to reduce inflammation and accelerate the healing process. This review focuses on the concept of skin tissue engineering, which is a modern approach to chronic wound treatment. The aim of the article is to summarize common therapies for chronic wounds and recent achievements in the development of bioengineered artificial skin constructs, including analysis of biomaterials and cells widely used for skin graft production. This review also presents attempts to reconstruct nerves, pigmentation, and skin appendages (hair follicles, sweat glands) using artificial skin grafts as well as recent trends in the engineering of biomaterials, aiming to produce nanocomposite skin substitutes (nanofilled polymer composites) with controlled antibacterial activity.
    [Show full text]
  • Artificial Skin in Robotics
    Artificial Skin in Robotics A Comprehensive Interface for System-Environment Interaction zur Erlangung des akademischen Grades eines Doktors der Ingenieurwissenschaften der Fakultät für Informatik des Karlsruher Instituts für Technologie (KIT) genehmigte Dissertation von Michael Strohmayr aus Augsburg Tag der mündlichen Prüfung: 14. Juni 2012 Erster Gutachter: Prof. Dr.-Ing. Heinz Wörn Zweiter Gutachter: Prof. Dr.-Ing. Gerd Hirzinger ii Eigenständigkeitserklärung Ich versichere wahrheitsgemäß, die Dissertation bis auf die dort angegebenen Hil- fen selbständig angefertigt, alle benutzten Hilfsmittel vollständig und genau angegeben und alles kenntlich gemacht zu haben, was aus Arbeiten anderer und eigenen Veröffentlichungen unverändert oder mit Änderungen entnommen wurde. München, den 26. April 2012 Michael Strohmayr iv Acknowledgments This thesis summarizes my research towards an artificial skin for robotic systems. The studies have been conducted during my time at the German Aerospace Center (DLR), Institute of Robotics and Mechatronics. I want to thank all who have given time, assistance and patience so generously. I would like to express my sincere gratitude to Prof. Dr.-Ing. Gerd Hirzinger for his trust and the opportunity to work under the most inspiring research conditions possible. The unique culture and open-mindedness at the institute made this the- sis possible in the first place. My special thanks go to Prof. Dr.-Ing. Heinz Wörn, head of the Institute for Pro- cess Control and Robotics, Karlsruhe Institute of Technology (KIT), for his advice and guidance during the composition of this thesis. I would like to thank all fellow researchers and friends for the fruitful discussions, constructive criticism and proofreading of the manuscript. Special thanks to Tim Bodenmüller, Ulrich Seibold, Ulrich Hagn, Robert Haslinger, Patrick Leyendecker, Michael Suppa, Georg Passig, Florian Fröhlich, Erhard Krampe, Klaus Schlicken- rieder, Björn Ernst, Thomas Haase and Andrea Strohmayr.
    [Show full text]
  • Bioengineered Skin Substitutes: Advances and Future Trends
    applied sciences Review Bioengineered Skin Substitutes: Advances and Future Trends Shima Tavakoli 1 and Agnes S. Klar 2,3,* 1 Department of Materials Engineering, Isfahan University of Technology, Isfahan 84156-83111, Iran; [email protected] 2 Tissue Biology Research Unit, University Children’s Hospital Zurich, University of Zurich, 8952 Schlieren, Switzerland 3 Children’s Research Center, University Children’s Hospital Zurich, 8032 Zurich, Switzerland * Correspondence: [email protected]; Tel.: +41-44-6348-819 Abstract: As the largest organ in the human body, the skin has the function of maintaining balance and protecting from external factors such as bacteria, chemicals, and temperature. If the wound does not heal in time after skin damage, it may cause infection or life-threatening complications. In particular, medical treatment of large skin defects caused by burns or trauma remains challenging. Therefore, human bioengineered skin substitutes represent an alternative approach to treat such injuries. Based on the chemical composition and scaffold material, skin substitutes can be classified into acellular or cellular grafts, as well as natural-based or synthetic skin substitutes. Further, they can be categorized as epidermal, dermal, and composite grafts, based on the skin component they contain. This review presents the common commercially available skin substitutes and their clinical use. Moreover, the choice of an appropriate hydrogel type to prepare cell-laden skin substitutes is discussed. Additionally, we present recent advances in the field of bioengineered human skin substitutes using three-dimensional (3D) bioprinting techniques. Finally, we discuss different skin substitute developments to meet different criteria for optimal wound healing. Keywords: bioengineered skin; skin substitute; hydrogel scaffolds; 3D bioprinting Citation: Tavakoli, S.; Klar, A.S.
    [Show full text]
  • Integra® Dermal Regeneration Template
    Integra® Dermal Regeneration Template Limit uncertainty with a proven Dermal Regeneration System Integra® Dermal Regeneration Template Outcomes Case 1 Left: Two-year-old neck scar contracture before Integra template treatment Right: Neck 1.5 years after contracture release and treatment with Integra template Case 2 Left: 14-year-old chest scar contracture before Integra template treatment Right: Chest 1 year after contracture release and treatment with Integra template Case 3 Left: Hand scar contracture before Integra template treatment Right: 5 weeks after release and treatment with Integra template patient regained functional use of hand Integra Template Promotes Regeneration of Dermal Tissue Integra® Dermal Regeneration Template (Integra Template) has two layers: a thin outer layer of silicone and a thick inner matrix layer of pure bovine collagen and glycosaminoglycan (GAG). Both collagen and GAG are normal components of human skin. In Integra, the collagen is obtained from bovine tendon collagen and the glycosaminoglycan is obtained from shark cartilage. Integra Template Indication Integra Dermal Regeneration Template is indicated for the postexcisional treatment of life-threatening, full-thickness or deep partial- thickness thermal injuries where sufficient autograft is not available at the time of excision or not desirable due to the physiological condition of the patient. Integra template is also indicated for the repair of scar contractures when other therapies have failed or when donor sites for repair are not sufficient or desirable
    [Show full text]
  • A Narrative Review of the History of Skin Grafting in Burn Care
    medicina Review A Narrative Review of the History of Skin Grafting in Burn Care Deepak K. Ozhathil *, Michael W. Tay, Steven E. Wolf and Ludwik K. Branski Department of Surgery, University of Texas Medical Branch at Galveston, Galveston, TX 77550, USA; [email protected] (M.W.T.); [email protected] (S.E.W.); [email protected] (L.K.B.) * Correspondence: [email protected]; Tel.: +1-508-654-8246 Abstract: Thermal injuries have been a phenomenon intertwined with the human condition since the dawn of our species. Autologous skin translocation, also known as skin grafting, has played an important role in burn wound management and has a rich history of its own. In fact, some of the oldest known medical texts describe ancient methods of skin translocation. In this article, we examine how skin grafting has evolved from its origins of necessity in the ancient world to the well-calibrated tool utilized in modern medicine. The popularity of skin grafting has ebbed and flowed multiple times throughout history, often suppressed for cultural, religious, pseudo-scientific, or anecdotal reasons. It was not until the 1800s, that skin grafting was widely accepted as a safe and effective treatment for wound management, and shortly thereafter for burn injuries. In the nineteenth and twentieth centuries skin grafting advanced considerably, accelerated by exponential medical progress and the occurrence of man-made disasters and global warfare. The introduction of surgical instruments specifically designed for skin grafting gave surgeons more control over the depth and consistency of harvested tissues, vastly improving outcomes. The invention of powered surgical instruments, such as the electric dermatome, reduced technical barriers for many surgeons, allowing the practice of skin grafting to be extended ubiquitously from a small group of technically gifted reconstructive surgeons Citation: Ozhathil, D.K.; Tay, M.W.; to nearly all interested sub-specialists.
    [Show full text]
  • Successful Application of Tissue Engineering Skin to Third Degree Burn Wound on Lateral Thorax: a Case Study
    Research Article ISSN: 2574 -1241 DOI: 10.26717/BJSTR.2019.16.002868 Successful Application of Tissue Engineering Skin to Third Degree Burn Wound on Lateral Thorax: A Case Study Jon Kee Ho, Huawei Shao, Chuangang You, Xuanliang Pan, Xingang Wang, Guoxian Chen, Abidullah Khan and Chunmao Han* Department of Burns and Wound Care, Second Affiliated Hospital of Zhejiang University, School of Medicine, Jiefang Road 88, Hangzhou 310009, China *Corresponding author: Chunmao Han, Department of Burns and Wound Care, Second Affiliated Hospital of Zhejiang University, School of Medicine, Jiefang Road 88, Hangzhou 310009, China ARTICLE INFO abstract Received: Published: March 11, 2019 Wounds on lateral thorax are hard to repair for its ®location makes skin-grafting a March 28, 2019 difficult task. For extensive burns, autologous skin is scarce. Therefore, in this case the Citation: artificial skin was used on the difficult wounds. ActivSkin® is tissue engineering skin with double layers containing epidermal cells and fibroblasts. It is mainly used for graft, and treat four- Jon Kee Ho, Huawei Shao, ment of burns.® The case in this study grafted ActivSkin to third degree burns on2 the left Chuangang You, Xuanliang Pan, Xingang thoracic wounds created after2 escharotomy. The grafted area was about 100cm® Wang, Guoxian Chen, Abidullah Khan, ActivSkin patches (20 cm / patch) were used in the treatment. The grafts survived on Chunmao Han. Successful Application the wound, and the epithelialization of the wound in area with ActivSkin was faster® than of Tissue Engineering Skin to Third other area without it. Seven weeks later, foreign genes were not detected on the wound.
    [Show full text]
  • Immunological Challenges Associated with Artificial Skin Grafts: Available Solutions and Stem Cells in Future Design of Synthetic Skin Saurabh Dixit1,2†, Dieudonné R
    Dixit et al. Journal of Biological Engineering (2017) 11:49 DOI 10.1186/s13036-017-0089-9 REVIEW Open Access Immunological challenges associated with artificial skin grafts: available solutions and stem cells in future design of synthetic skin Saurabh Dixit1,2†, Dieudonné R. Baganizi1†, Rajnish Sahu1†, Ejowke Dosunmu1, Atul Chaudhari1, Komal Vig1, Shreekumar R. Pillai1, Shree R. Singh1 and Vida A. Dennis1* Abstract The repair or replacement of damaged skins is still an important, challenging public health problem. Immune acceptance and long-term survival of skin grafts represent the major problem to overcome in grafting given that in most situations autografts cannot be used. The emergence of artificial skin substitutes provides alternative treatment with the capacity to reduce the dependency on the increasing demand of cadaver skin grafts. Over the years, considerable research efforts have focused on strategies for skin repair or permanent skin graft transplantations. Available skin substitutes include pre- or post-transplantation treatments of donor cells, stem cell-based therapies, and skin equivalents composed of bio-engineered acellular or cellular skin substitutes. However, skin substitutes are still prone to immunological rejection, and as such, there is currently no skin substitute available to overcome this phenomenon. This review focuses on the mechanisms of skin rejection and tolerance induction and outlines in detail current available strategies and alternatives that may allow achieving full-thickness skin replacement and repair. Keywords: Skin allograft, Immune rejection, Biomaterial, Scaffolds, Stem cells, Skin tissue engineering, Skin substitutes Background severe skin injuries to protect the exposed layers of skin The skin, a subcomponent of the integumentary system, and allow the damaged portion to reform.
    [Show full text]